MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale and
issuance of common stock...
$91,075K
Proceeds from exercises
of common stock...
$366K
Proceeds from issuance of
common stock under...
$195K
Net cash provided by
financing activities
$89,249K
Canceled cashflow
$2,387K
Net (decrease)
increase in cash and cash...
-$14,590K
Canceled cashflow
$89,249K
Accrued liabilities
$6,415K
Stock-based compensation
expense
$3,948K
Non-cash lease expense
$380K
Accounts payable
$239K
Depreciation expense
$36K
Unrealized loss on
short-term investments
-$5K
Maturities/sales of short-term
investments
$80,027K
Financing costs paid in
connection with initial...
$2,387K
Net cash used in
operating activities
-$54,172K
Canceled cashflow
$11,023K
Net cash used in
investing activities
-$49,667K
Canceled cashflow
$80,027K
Net loss
-$57,591K
Prepaid expenses and
other assets
$5,960K
Amortization of discount on
short-term investments
$1,306K
Operating lease liability
-$338K
Purchases of short-term
investments
$129,599K
Purchases of property and
equipment
$95K
Back
Back
Cash Flow
source: myfinsight.com
Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc. (AARD)